MA28174A1 - Utilisation d'inhibiteurs de cathepsine k dans des maladies de la perte osseuse severe - Google Patents

Utilisation d'inhibiteurs de cathepsine k dans des maladies de la perte osseuse severe

Info

Publication number
MA28174A1
MA28174A1 MA29052A MA29052A MA28174A1 MA 28174 A1 MA28174 A1 MA 28174A1 MA 29052 A MA29052 A MA 29052A MA 29052 A MA29052 A MA 29052A MA 28174 A1 MA28174 A1 MA 28174A1
Authority
MA
Morocco
Prior art keywords
cathepsin
inhibitors
diseases
bone loss
severe bone
Prior art date
Application number
MA29052A
Other languages
English (en)
Inventor
Martin Missbach
Rainer Gamse
Ulrich Trechsel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28174A1 publication Critical patent/MA28174A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

De manière générale, la présente invention a trait à des inhibiteurs de cathepsine K et à leur utilisations dans la croissance osseuse. De manière spécifique, la présente invention a trait à l'utilisation d'inhibiteurs de cathepsine K pour la stimulation de nouvelle formation osseuse chez des patients qui en ont besoin.
MA29052A 2003-11-19 2006-05-24 Utilisation d'inhibiteurs de cathepsine k dans des maladies de la perte osseuse severe MA28174A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03026430 2003-11-19

Publications (1)

Publication Number Publication Date
MA28174A1 true MA28174A1 (fr) 2006-09-01

Family

ID=34610055

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29052A MA28174A1 (fr) 2003-11-19 2006-05-24 Utilisation d'inhibiteurs de cathepsine k dans des maladies de la perte osseuse severe

Country Status (16)

Country Link
US (1) US20070135448A1 (fr)
EP (1) EP1686995A1 (fr)
JP (1) JP2007511548A (fr)
KR (1) KR20060107792A (fr)
CN (1) CN1882343A (fr)
AU (1) AU2004290874A1 (fr)
BR (1) BRPI0416755A (fr)
CA (1) CA2545723A1 (fr)
IL (1) IL175436A0 (fr)
IS (1) IS8498A (fr)
MA (1) MA28174A1 (fr)
MX (1) MXPA06005635A (fr)
NO (1) NO20062870L (fr)
TN (1) TNSN06147A1 (fr)
TW (1) TW200526198A (fr)
WO (1) WO2005049028A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US20080076723A1 (en) * 2006-09-27 2008-03-27 Sylvan Pharmaceuticals Pty Ltd. Inhibition of cathepsin K activity and the treatment and prevention of disease
WO2008104271A2 (fr) 2007-02-28 2008-09-04 Sanofi-Aventis Sondes d'imagerie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
SK6572000A3 (en) * 1997-11-05 2000-10-09 Novartis Ag Dipeptide nitriles, process for the preparation thereof, their use as medicaments and pharmaceutical composition comprising them
JP3892187B2 (ja) * 1998-11-12 2007-03-14 生化学工業株式会社 環状アミド誘導体
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
CA2532948A1 (fr) * 2003-07-21 2005-02-17 Novartis Ag Combinaisons d'un inhibiteur de cathepsine k et d'un bisphophonate utilisees dans le traitement des metastases osseuses, de la croissance des tumeurs et de la perte osseuse induite par une tumeur

Also Published As

Publication number Publication date
IS8498A (is) 2006-06-06
CA2545723A1 (fr) 2005-06-02
TW200526198A (en) 2005-08-16
NO20062870L (no) 2006-08-18
KR20060107792A (ko) 2006-10-16
AU2004290874A1 (en) 2005-06-02
IL175436A0 (en) 2008-04-13
MXPA06005635A (es) 2006-08-17
JP2007511548A (ja) 2007-05-10
CN1882343A (zh) 2006-12-20
TNSN06147A1 (en) 2007-11-15
EP1686995A1 (fr) 2006-08-09
BRPI0416755A (pt) 2007-02-27
WO2005049028A1 (fr) 2005-06-02
US20070135448A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2003103575A3 (fr) Composes, compositions et procedes
EP1809280A4 (fr) Inhibiteurs de la kinesine mitotique et methodes d'utilisation desdits inhibiteurs
DE60211937D1 (de) Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
ATE511753T1 (de) Postnatale stammzellen und deren verwendungen
ATE535236T1 (de) Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit
AU3831301A (en) Method for treating ocular pain
MY134110A (en) Combinations of reboxetine and neuroleptic agents
EP1687449A4 (fr) Modulation antisens de l'expression de la proteine de type kinesine 1
WO2002034753A3 (fr) Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione
ATE311371T1 (de) Nicht-peptide inhibitoren von vla-4 abhängiger zellbindung für die behandlung von entzündungen, autoimmune krankheiten und atemstörungen
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
CA2330807A1 (fr) Utilisation d'inhibiteurs de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
YU78701A (sh) Tretiranje neurotskih poremećaja
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
MA28174A1 (fr) Utilisation d'inhibiteurs de cathepsine k dans des maladies de la perte osseuse severe
TR200200278T2 (tr) Kalsilitik bileşimler
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
NO20045089L (no) Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser
WO2003105754A3 (fr) Modulation antisens de l'expression du facteur de croissance endotheliale vasculaire b (vegf-b)
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
AU2002358652A1 (en) Method for determining the activity of ornithine decarboxylase and for identifying effectors of ornithine decarboxylase activity